I am a physician scientist with clinical training in internal medicine, nephrology and hypertension.  I am clinically active in the Vanderbilt Hypertension clinic, which focuses on evaluation and treatment of resistant and secondary forms of hypertension.

The goal of my translational research program is to discover mechanisms of hypertension and complications, through studies in animals and humans. My specialized research expertise includes clinical study design related to metabolism (insulin resistance and secretion) and hypertension.

Research in the Luther lab is multidisciplinary crossing the fields of pharmacology, endocrinology, nephrology, and biochemistry.  We have developed collaborations with investigators with a common interest in translational research to apply state-of-the-art technology to advance our clinical studies.

We have demonstrated that aldosterone, a hormone which regulates blood pressure, produces inflammation and impairs insulin secretion in humans. Using a proteomic approach, we have has also identified novel biomarkers of kidney sodium channel activation in humans.  Additionally, we have demonstrated that the arachidonic acid CYP450 metabolite epoxyeicosatrienoic acid is associated with insulin sensitivity in mice and in humans.   


The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Early urine electrolyte patterns in patients with acute heart failure. Collins SP, Jenkins CA, Baughman A, Miller KF, Storrow AB, Han JH, Brown NJ, Liu D, Luther JM, McNaughton CD, Self WH, Peng D, Testani JM, Lindenfeld J (2019) ESC Heart Fail 6(1): 80-88
    › Primary publication · 30295437 (PubMed) · PMC6351901 (PubMed Central)
  2. Co-Prescription of Strong CYP1A2 Inhibitors and the Risk of Tizanidine-Associated Hypotension: A Retrospective Cohort Study. Chaugai S, Dickson AL, Shuey MM, Feng Q, Barker KA, Wei WQ, Luther JM, Stein CM, Chung CP (2019) Clin Pharmacol Ther 105(3): 703-709
    › Primary publication · 30223305 (PubMed) · PMC6379114 (PubMed Central)
  3. The Cytochrome P450 Slow Metabolizers CYP2C9*2 and CYP2C9*3 Directly Regulate Tumorigenesis via Reduced Epoxyeicosatrienoic Acid Production. Sausville LN, Gangadhariah MH, Chiusa M, Mei S, Wei S, Zent R, Luther JM, Shuey MM, Capdevila JH, Falck JR, Guengerich FP, Williams SM, Pozzi A (2018) Cancer Res 78(17): 4865-4877
    › Primary publication · 30012669 (PubMed) · PMC6125168 (PubMed Central)
  4. Cytochrome P450 epoxygenase-derived epoxyeicosatrienoic acids contribute to insulin sensitivity in mice and in humans. Gangadhariah MH, Dieckmann BW, Lantier L, Kang L, Wasserman DH, Chiusa M, Caskey CF, Dickerson J, Luo P, Gamboa JL, Capdevila JH, Imig JD, Yu C, Pozzi A, Luther JM (2017) Diabetologia 60(6): 1066-1075
    › Primary publication · 28352940 (PubMed) · PMC5921930 (PubMed Central)
  5. Hyperinsulinemia and Insulin Resistance in Dopamine β-Hydroxylase Deficiency. Arnold AC, Garland EM, Celedonio JE, Raj SR, Abumrad NN, Biaggioni I, Robertson D, Luther JM, Shibao CA (2017) J Clin Endocrinol Metab 102(1): 10-14
    › Primary publication · 27778639 (PubMed) · PMC5413093 (PubMed Central)
  6. Epoxyeicosatrienoic acids and glucose homeostasis in mice and men. Luther JM, Brown NJ (2016) Prostaglandins Other Lipid Mediat : 2-7
    › Primary publication · 27448715 (PubMed) · PMC5035218 (PubMed Central)
  7. Hyperglycemic clamp-derived disposition index is negatively associated with metabolic syndrome severity in obese subjects. Shah SS, Ramirez CE, Powers AC, Yu C, Shibao CA, Luther JM (2016) Metabolism 65(6): 835-42
    › Primary publication · 27173462 (PubMed) · PMC4867079 (PubMed Central)
  8. Treatment with Sildenafil Improves Insulin Sensitivity in Prediabetes: A Randomized, Controlled Trial. Ramirez CE, Nian H, Yu C, Gamboa JL, Luther JM, Brown NJ, Shibao CA (2015) J Clin Endocrinol Metab 100(12): 4533-40
    › Primary publication · 26580240 (PubMed) · PMC4667163 (PubMed Central)
  9. Aldosterone in vascular and metabolic dysfunction. Luther JM (2016) Curr Opin Nephrol Hypertens 25(1): 16-21
    › Primary publication · 26575396 (PubMed) · PMC4824306 (PubMed Central)
  10. Activation of the Endogenous Renin-Angiotensin-Aldosterone System or Aldosterone Administration Increases Urinary Exosomal Sodium Channel Excretion. Qi Y, Wang X, Rose KL, MacDonald WH, Zhang B, Schey KL, Luther JM (2016) J Am Soc Nephrol 27(2): 646-56
    › Primary publication · 26113616 (PubMed) · PMC4731116 (PubMed Central)
  11. Proteomics characterization of exosome cargo. Schey KL, Luther JM, Rose KL (2015) Methods : 75-82
    › Primary publication · 25837312 (PubMed) · PMC4591097 (PubMed Central)
  12. Effects of aldosterone on insulin sensitivity and secretion. Luther JM (2014) Steroids : 54-60
    › Primary publication · 25194457 (PubMed) · PMC4252580 (PubMed Central)
  13. Arg287Gln variant of EPHX2 and epoxyeicosatrienoic acids are associated with insulin sensitivity in humans. Ramirez CE, Shuey MM, Milne GL, Gilbert K, Hui N, Yu C, Luther JM, Brown NJ (2014) Prostaglandins Other Lipid Mediat : 38-44
    › Primary publication · 25173047 (PubMed) · PMC4253976 (PubMed Central)
  14. Hypertension is a major contributor to 20-hydroxyeicosatetraenoic acid-mediated kidney injury in diabetic nephropathy. Gangadhariah MH, Luther JM, Garcia V, Paueksakon P, Zhang MZ, Hayward SW, Love HD, Falck JR, Manthati VL, Imig JD, Schwartzman ML, Zent R, Capdevila JH, Pozzi A (2015) J Am Soc Nephrol 26(3): 597-610
    › Primary publication · 25071086 (PubMed) · PMC4341468 (PubMed Central)
  15. Dietary sodium restriction decreases insulin secretion without affecting insulin sensitivity in humans. Luther JM, Byrne LM, Yu C, Wang TJ, Brown NJ (2014) J Clin Endocrinol Metab 99(10): E1895-902
    › Primary publication · 25029426 (PubMed) · PMC4184066 (PubMed Central)
  16. Is there a new dawn for selective mineralocorticoid receptor antagonism? Luther JM (2014) Curr Opin Nephrol Hypertens 23(5): 456-61
    › Primary publication · 24992570 (PubMed) · PMC4248353 (PubMed Central)
  17. Human interventions to characterize novel relationships between the renin-angiotensin-aldosterone system and parathyroid hormone. Brown JM, Williams JS, Luther JM, Garg R, Garza AE, Pojoga LH, Ruan DT, Williams GH, Adler GK, Vaidya A (2014) Hypertension 63(2): 273-80
    › Primary publication · 24191286 (PubMed) · PMC3898197 (PubMed Central)
  18. Fenofibrate lowers blood pressure in salt-sensitive but not salt-resistant hypertension. Gilbert K, Nian H, Yu C, Luther JM, Brown NJ (2013) J Hypertens 31(4): 820-9
    › Primary publication · 23385647 (PubMed) · PMC3800119 (PubMed Central)
  19. Aldosterone deficiency prevents high-fat-feeding-induced hyperglycaemia and adipocyte dysfunction in mice. Luo P, Dematteo A, Wang Z, Zhu L, Wang A, Kim HS, Pozzi A, Stafford JM, Luther JM (2013) Diabetologia 56(4): 901-10
    › Primary publication · 23314847 (PubMed) · PMC3593801 (PubMed Central)
  20. Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II-induced cardiac, renal, and vascular injury. Luther JM, Luo P, Wang Z, Cohen SE, Kim HS, Fogo AB, Brown NJ (2012) Kidney Int 82(6): 643-51
    › Primary publication · 22622494 (PubMed) · PMC3434275 (PubMed Central)
  21. Patient knowledge of blood pressure target is associated with improved blood pressure control in chronic kidney disease. Wright-Nunes JA, Luther JM, Ikizler TA, Cavanaugh KL (2012) Patient Educ Couns 88(2): 184-8
    › Primary publication · 22459637 (PubMed) · PMC3404190 (PubMed Central)
  22. Comparative effects of angiotensin-converting enzyme inhibition and angiotensin-receptor blockade on inflammation during hemodialysis. Gamboa JL, Pretorius M, Todd-Tzanetos DR, Luther JM, Yu C, Ikizler TA, Brown NJ (2012) J Am Soc Nephrol 23(2): 334-42
    › Primary publication · 22158433 (PubMed) · PMC3269170 (PubMed Central)
  23. Proteomic analysis of urine exosomes by multidimensional protein identification technology (MudPIT). Wang Z, Hill S, Luther JM, Hachey DL, Schey KL (2012) Proteomics 12(2): 329-38
    › Primary publication · 22106071 (PubMed) · PMC3517144 (PubMed Central)
  24. The renin-angiotensin-aldosterone system and glucose homeostasis. Luther JM, Brown NJ (2011) Trends Pharmacol Sci 32(12): 734-9
    › Primary publication · 21880378 (PubMed) · PMC3223326 (PubMed Central)
  25. Aldosterone decreases glucose-stimulated insulin secretion in vivo in mice and in murine islets. Luther JM, Luo P, Kreger MT, Brissova M, Dai C, Whitfield TT, Kim HS, Wasserman DH, Powers AC, Brown NJ (2011) Diabetologia 54(8): 2152-63
    › Primary publication · 21519965 (PubMed) · PMC3216479 (PubMed Central)
  26. Protein profile of exosomes from trabecular meshwork cells. Stamer WD, Hoffman EA, Luther JM, Hachey DL, Schey KL (2011) J Proteomics 74(6): 796-804
    › Primary publication · 21362503 (PubMed) · PMC3085584 (PubMed Central)
  27. Pharmacokinetics of acyclovir and its metabolites in cerebrospinal fluid and systemic circulation after administration of high-dose valacyclovir in subjects with normal and impaired renal function. Smith JP, Weller S, Johnson B, Nicotera J, Luther JM, Haas DW (2010) Antimicrob Agents Chemother 54(3): 1146-51
    › Primary publication · 20038622 (PubMed) · PMC2825963 (PubMed Central)
  28. Endogenous bradykinin contributes to increased plasminogen activator inhibitor 1 antigen following hemodialysis. Marney AM, Ma J, Luther JM, Ikizler TA, Brown NJ (2009) J Am Soc Nephrol 20(10): 2246-52
    › Primary publication · 19628666 (PubMed) · PMC2754101 (PubMed Central)
  29. Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt. Lea WB, Kwak ES, Luther JM, Fowler SM, Wang Z, Ma J, Fogo AB, Brown NJ (2009) Kidney Int 75(9): 936-44
    › Primary publication · 19225557 (PubMed) · PMC2770712 (PubMed Central)
  30. Endogenous aldosterone contributes to acute angiotensin II-stimulated plasminogen activator inhibitor-1 and preproendothelin-1 expression in heart but not aorta. Luther JM, Wang Z, Ma J, Makhanova N, Kim HS, Brown NJ (2009) Endocrinology 150(5): 2229-36
    › Primary publication · 19106220 (PubMed) · PMC2671907 (PubMed Central)
  31. Blood pressure targets in hemodialysis patients. Luther JM, Golper TA (2008) Kidney Int 73(6): 667-8
    › Primary publication · 18309346 (PubMed)
  32. 17Beta-estradiol increases basal but not bradykinin-stimulated release of active t-PA in young postmenopausal women. Pretorius M, van Guilder GP, Guzman RJ, Luther JM, Brown NJ (2008) Hypertension 51(4): 1190-6
    › Primary publication · 18259028 (PubMed) · PMC2673569 (PubMed Central)
  33. Bradykinin type 2 receptor BE1 genotype influences bradykinin-dependent vasodilation during angiotensin-converting enzyme inhibition. Van Guilder GP, Pretorius M, Luther JM, Byrd JB, Hill K, Gainer JV, Brown NJ (2008) Hypertension 51(2): 454-9
    › Primary publication · 18180402 (PubMed) · PMC2581632 (PubMed Central)
  34. The bradykinin type 2 receptor BE1 polymorphism and ethnicity influence systolic blood pressure and vascular resistance. Pretorius MM, Gainer JV, Van Guilder GP, Coelho EB, Luther JM, Fong P, Rosenbaum DD, Malave HA, Yu C, Ritchie MD, Vaughan DE, Brown NJ (2008) Clin Pharmacol Ther 83(1): 122-9
    › Primary publication · 17522594 (PubMed)
  35. Angiotensin II induces interleukin-6 in humans through a mineralocorticoid receptor-dependent mechanism. Luther JM, Gainer JV, Murphey LJ, Yu C, Vaughan DE, Morrow JD, Brown NJ (2006) Hypertension 48(6): 1050-7
    › Primary publication · 17043157 (PubMed)
  36. Bradykinin and its metabolite bradykinin 1-5 inhibit thrombin-induced platelet aggregation in humans. Murphey LJ, Malave HA, Petro J, Biaggioni I, Byrne DW, Vaughan DE, Luther JM, Pretorius M, Brown NJ (2006) J Pharmacol Exp Ther 318(3): 1287-92
    › Primary publication · 16772538 (PubMed)
  37. Angiotensin-converting enzyme inhibition increases basal vascular tissue plasminogen activator release in women but not in men. Pretorius M, Luther JM, Murphey LJ, Vaughan DE, Brown NJ (2005) Arterioscler Thromb Vasc Biol 25(11): 2435-40
    › Primary publication · 16166566 (PubMed)
  38. Utility of bone marrow biopsy for rapid diagnosis of febrile illnesses in patients with human immunodeficiency virus infection. Luther JM, Lakey DL, Larson RS, Kallianpur AR, D'Agata E, Cousar JB, Haas DW (2000) South Med J 93(7): 692-7
    › Primary publication · 10923958 (PubMed)